|Description||GSK 269962 is a potent ROCK inhibitor with IC50 values are 1.6 and 4 nM for recombinant human ROCK1 and ROCK2 respectively, which displays greater than 30-fold selectivity for ROCK against a panel of serine/threonine kinases. It may be used in OAB treatment. It has been shown to block the generation of inflammatory cytokines in lipopolysaccharide-stimulated monocytes and to induce vasorelaxation in preconstricted rat aorta (IC50 = 35 nM). It lowers blood pressure in a rat model of hypertension. It induced a reduction in blood pressure of approximately 10, 20, and 50 mm Hg at doses of 1, 3, and 30 mg/kg. It represent a novel class of ROCK inhibitors that have profound effects in the vasculature, which may enable us to further evaluate the potential beneficial effects of ROCK inhibition in animal models of cardiovascular as well as other chronic diseases.|
|Solubility||10 mM in DMSO|
|Application||GSK 269962 may be used in OAB treatment. It represent a novel class of ROCK inhibitors.|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Density||1.45±0.1 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr|
A potent inhibitor of ROCK2 (IC50= 1.2 nM)
Verosudil is a selective Rho-kinase inhibitor originated by Aerie Pharmaceuticals. In Jun 2013, Phase-II for Ocular hypertension in USA was discontinued. In Sep...
Y-27632 2HCl inhibits ROCK-II while displaying little activity against PKC, cAMP-dependent protein kinase and myosin light-chain kinase (MLCK) with Ki of 26 μM,...
SAR-407899 is a potent, ATP-competitive ROCK inhibitor. It is equipotent against human and rat-derived Rho-kinase 2 with inhibition constant values of 36 nM and...
K-115, also called as Ripasudil or Glanatec, a selective ROCK inhibitor (IC50 =31 nM), is a promising emerging antiglaucoma drug, and was thus approved by the J...
GSK429286A is a selective inhibitor of ROCK1 and ROCK2 with IC50 of 14 nM and 63 nM, respectively.
Y-33075, also called as SNJ-1656, a well-characterized ROCK inhibitor, inhibits more potently ROCK by about 30 times than Y-27632, a common specific ROCK inhibi...
Fasudil is a potent and selective Rho-kinase (ROCK) inhibitor and vasodilator. ROCK is an enzyme that participates in vasoconstriction and vascular remodeling. ...
ZINC00881524 is a specific ROCK inhibitor.
Fasudil HCl, a 5-isoquinolinesulfonamide derivative, is a highly selective Rho-associated protein kinase inhibitor that might have a rate in romoting the recove...
GSK180736A is a selective GRK2 inhibitor with an IC50 of 0.77 μM. It is also a weak inhibitor of PKA with an IC50 of 30 μM, but highly potent against ROCK1 (IC5...
GSK 269962 is a potent ROCK inhibitor with IC50 values are 1.6 and 4 nM for recombinant human ROCK1 and ROCK2 respectively, which displays greater than 30-fold ...
Hydroxyfasudil Hydrochloride, an active metabolite of Fasudil, preferentially inhibits Rho-kinase and plays a central role in the pathogenesis of coronary arter...
SAR-407899 hydrochloride is the hydrochloride form of SAR-407899, which is a potent, ATP-competitive ROCK inhibitor. It has good antihypertensive activity.
Y-33075 dihydrochloride is a selective ROCK inhibitor (IC50= 3.6nM) derived from Y-27632, and is more potent than Y-27632.
Ripasudil (K-115) is potent ROCK inhibitor with IC50 of 51 nM and 19 nM for ROCK1 and ROCK2, respectively, used for the treatment of glaucoma and ocular hyperte...
6-Chloro-n4-[3,5-difluoro-4-[(3-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl]-2,4-pyrimidinediamine is potent and highly selective ROCK inhibitor. Its IC50 v...